Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A.
OBJECTIVE
To determine hip radiographic findings in children with cerebral palsy (CP) treated with botulinum toxin type A (BTX-A).


METHODS
Retrospective chart review with correlation to radiographic findings.


METHODS
Academic center.


METHODS
Sixteen subjects with CP.


METHODS
BTX-A treatment to adductor muscles.


METHODS
The Reimers hip migration percentage before and after BTX-A.


RESULTS
Thirty-two hips in 16 children with CP were treated. We examined the effect of initial migration percentage and initial migration percentage age on the change in migration percentage after BTX-A injection. A significant effect for initial migration percentage (<30% or >/=30%; F=19.05, P <.001) and a significant interaction between initial migration percentage and initial migration percentage age (F=7.5, P <.01) was noted. Initial migration percentage age (</=24 mo or >24 mo) was not significant (F=.95, P =.34). Patients who had an initial migration percentage of 30% or more and were less than 24 months old were more likely to have a decrease in migration percentage after BTX-A injection compared with patients who were older than 24 months and who had an initial migration percentage of 30% or more.


CONCLUSIONS
Improvement in hip migration percentage after BTX-A injection is a function of age and the initial migration percentage. BTX-A injections to adductor muscles may be beneficial for some children with CP.
Pidcock
Frank S
FS
Department of Physical Medicine and Rehabilitation, Baltimore, MD, USA. pidcock@kennedykrieger.org
Fish
David E
DE
Johnson-Greene
Doug
D
Borras
Isabel
I
McGready
John
J
Silberstein
Charles E
CE
D000375:Aging; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000534:rehabilitation; D002675:Child, Preschool; D005260:Female; D006615:Hip / Q000000981:diagnostic imaging*; D006801:Humans; D007223:Infant; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011859:Radiography; D012189:Retrospective Studies
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A